<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048165</url>
  </required_header>
  <id_info>
    <org_study_id>NR15880</org_study_id>
    <nct_id>NCT00048165</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation</brief_title>
  <official_title>A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the number of randomized participants in each
      treatment group who experience an acute rejection episode in the first 6 months after
      undergoing cardiac transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant</measure>
    <time_frame>Up to 6 months PT</time_frame>
    <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months post-transplant (PT). Participants with acute rejection included participants with a biopsy histology of International Society of Heart and Lung Transplant (ISHLT) Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT</measure>
    <time_frame>Up to 12 months PT</time_frame>
    <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months. Participants with acute rejection included participants with a biopsy histology of ISHLT Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT</measure>
    <time_frame>Within 6 months and 12 months PT</time_frame>
    <description>The number of participants with 0,1, 2, 3 or 4 episodes at 6 and 12 months PT were reported. An episode of acute rejection was defined according to the date of positive biopsy of Grade IIIA or worse or the date of start of treatment for HDC, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT</measure>
    <time_frame>At 6 months, 12 months , 3 years PT</time_frame>
    <description>The survival of the graft and participants at 6,12 months and 3 years PT was reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT</measure>
    <time_frame>Within 6 months and 12 months PT</time_frame>
    <description>The number of participants with Worst International Society of Heart and Lung Transplant (ISHLT) grade within first 6 months and 12 months PT were reported. ISHLT is a standardized grading method to determine the acute cellular rejection on endomyocardial biopsy ; where 0= no rejection, IA= focal (perivascular or interstitial) infiltrate without necrosis, IB= diffuse but sparse infiltrate without necrosis, II=one focus only with aggressive infiltration and/or focal myocyte damage, IIIA=multifocal aggressive infiltrates and/or myocyte damage, IIIB= diffuse inflammatory process with necrosis, IV= diffuse aggressive polymorphous and/or infiltrate and/or edema and/or hemorrhage and/or vasculitis, with necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT</measure>
    <time_frame>Within 6 months and 12 months PT</time_frame>
    <description>The median time to first acute rejection episode within first 6 months and 12 months PT was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT</measure>
    <time_frame>Within 6 months and 12 months PT</time_frame>
    <description>The number of participants who received monomurab Cluster of differentiation 3, orthoclone, polyclonal antithymocyte globulin or antilymphocyte globulin for treatment of biopsy proven rejection or HDC within 6 and 12 months PT were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT</measure>
    <time_frame>Within 6 months and 12 months PT</time_frame>
    <description>The maintenance doses of mycophenolate mofetil (1.5g twice a day daily), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg oral [PO]/nasogastric [NG] within 72 hours post-operative]), and cumulative dose of corticosteroids (500-1000 mg IV methylprednisolone pre-operative switched to oral at 0.5-1 mg/kg/day. Tapered to 0.2 mg/kg/d by Day 28, 0.1-0.15 mg/kg/day from Days 36 to 90, and 0.1-0.15 mg/kg/day from Days 120 to 180)at 6 and 12 months PT were reported. Maintenance dose was calculated as total dose per day summed over all days that a participant was administered drug within the specified time interval, divided by number of days that a participant took drug within that time interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)</measure>
    <time_frame>From Baseline (Day -2) to 3 months and 6 months</time_frame>
    <description>Lipid profile included total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL), and triglycerides (all total cholesterol, LDL, HDL, and triglycerides with unit milligram per decilitre [mg/dL]), were reported. The median change from baseline (Day -2) in lipid profile values at 3 months and 6 months was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline for LDL/HDL Ratio</measure>
    <time_frame>From Baseline (Day -2) to 3 months, and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Hematology included hemoglobin, hematocrit, white blood cell count (WBC) with differential (including granulocytes or neutrophils, basophils, eosinophils, monocytes, lymphocytes), platelets, and erythrocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Biochemistry included blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), phosphorous, total bilirubin, direct bilirubin, total protein, albumin, glucose, alkaline phosphatase, low density lipoprotein (LDH), uric acid, carbon dioxide, magnesium, sodium, potassium, chloride, calcium, LDL, HDL, total cholesterol, and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during this study were reported as AEs. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Malignancies and Opportunistic Infections</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The opportunistic infections included infections with Cytomegalovirus, Aspergillus, Candida, Pneumocystis, Cryptococcus, Listeria, Herpes simplex, Herpes zoster. For malignancy, participants with any type of malignancy whose date of onset or diagnosis was after randomization was reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">434</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Daclizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.</description>
    <arm_group_label>Daclizumab</arm_group_label>
    <other_name>Zenapax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).</description>
    <arm_group_label>Daclizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.</description>
    <arm_group_label>Daclizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered on Days 1, 8, 22, 36, and 50.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.</description>
    <arm_group_label>Daclizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be undergoing their first cardiac allograft transplant

          -  Women of childbearing potential must have a negative serum pregnancy test within 48
             hours prior to transplantation

          -  Women of childbearing potential must use two reliable forms of contraception
             simultaneously. Effective contraception must be used before beginning study drug
             therapy, and for 4 months following discontinuation of study drug therapy

          -  Participants and/or their guardians must be willing and be capable of understanding
             risks and comply with the purpose of the study

        Exclusion Criteria:

          -  Previous organ transplants

          -  Participants receiving multiple organs

          -  Participants requiring ventricular assist device (VAD) upon completion of
             transplantation surgery

          -  Women lactating, pregnant or of childbearing potential not using, or who are unwilling
             to use two reliable forms of contraception simultaneously during the study

          -  History of a psychological illness or condition which would interfere with the
             participant's ability to understand the requirements of the study

          -  White blood count =&lt;2500/mm^3, platelets =&lt;50,000/mm^3 or hemoglobin =&lt;6 g/dL

          -  HIV-1, the presence of positive HBsAg, or chronic active hepatitis C

          -  Active peptic ulcer disease

          -  Severe diarrhea or other gastrointestinal disorders which might interfere with their
             ability to absorb oral medication

          -  Malignancies within the past 5 years, excluding skin carcinoma that have been
             adequately treated

          -  Participants who have received within the past 30 days or require concomitant
             treatment with other investigational drugs or immunosuppressive medications that are
             prohibited for this study

          -  Inability to start microemulsion form of cyclosporine within 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-2221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goeteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2002</study_first_submitted>
  <study_first_submitted_qc>October 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2002</study_first_posted>
  <results_first_submitted>May 4, 2016</results_first_submitted>
  <results_first_submitted_qc>May 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2016</results_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted across 31 centers in four countries from 28 Aug 1999 to 19 Aug 2002.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Daclizumab</title>
          <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed 6 Months Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administration/Other</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormality of laboratory test</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event/intermittent illness</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed 12 Months Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administration/Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not co-operate/Withdrew</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
      <group_list>
        <group group_id="B1">
          <title>Daclizumab</title>
          <description>Eligible participants were administered an intravenous daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Eligible participants were administered an intravenous matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="216"/>
            <count group_id="B2" value="218"/>
            <count group_id="B3" value="434"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="11.75"/>
                    <measurement group_id="B2" value="53.1" spread="11.89"/>
                    <measurement group_id="B3" value="52.8" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant</title>
        <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months post-transplant (PT). Participants with acute rejection included participants with a biopsy histology of International Society of Heart and Lung Transplant (ISHLT) Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up.</description>
        <time_frame>Up to 6 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant</title>
          <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months post-transplant (PT). Participants with acute rejection included participants with a biopsy histology of International Society of Heart and Lung Transplant (ISHLT) Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>percent mean difference</param_type>
            <param_value>-12.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.9</ci_lower_limit>
            <ci_upper_limit>-3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT</title>
        <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months. Participants with acute rejection included participants with a biopsy histology of ISHLT Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up</description>
        <time_frame>Up to 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT</title>
          <description>The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months. Participants with acute rejection included participants with a biopsy histology of ISHLT Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.063</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>percent mean difference</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT</title>
        <description>The number of participants with 0,1, 2, 3 or 4 episodes at 6 and 12 months PT were reported. An episode of acute rejection was defined according to the date of positive biopsy of Grade IIIA or worse or the date of start of treatment for HDC, whichever came first.</description>
        <time_frame>Within 6 months and 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT</title>
          <description>The number of participants with 0,1, 2, 3 or 4 episodes at 6 and 12 months PT were reported. An episode of acute rejection was defined according to the date of positive biopsy of Grade IIIA or worse or the date of start of treatment for HDC, whichever came first.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 6 months, 0 episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, 1 episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, 2 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, 3 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, 4 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, 0 episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, 1 episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, 2 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, 3 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, 4 episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT</title>
        <description>The survival of the graft and participants at 6,12 months and 3 years PT was reported</description>
        <time_frame>At 6 months, 12 months , 3 years PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT</title>
          <description>The survival of the graft and participants at 6,12 months and 3 years PT was reported</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not collected</measurement>
                    <measurement group_id="O2" value="NA">Data was not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT</title>
        <description>The number of participants with Worst International Society of Heart and Lung Transplant (ISHLT) grade within first 6 months and 12 months PT were reported. ISHLT is a standardized grading method to determine the acute cellular rejection on endomyocardial biopsy ; where 0= no rejection, IA= focal (perivascular or interstitial) infiltrate without necrosis, IB= diffuse but sparse infiltrate without necrosis, II=one focus only with aggressive infiltration and/or focal myocyte damage, IIIA=multifocal aggressive infiltrates and/or myocyte damage, IIIB= diffuse inflammatory process with necrosis, IV= diffuse aggressive polymorphous and/or infiltrate and/or edema and/or hemorrhage and/or vasculitis, with necrosis</description>
        <time_frame>Within 6 months and 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT</title>
          <description>The number of participants with Worst International Society of Heart and Lung Transplant (ISHLT) grade within first 6 months and 12 months PT were reported. ISHLT is a standardized grading method to determine the acute cellular rejection on endomyocardial biopsy ; where 0= no rejection, IA= focal (perivascular or interstitial) infiltrate without necrosis, IB= diffuse but sparse infiltrate without necrosis, II=one focus only with aggressive infiltration and/or focal myocyte damage, IIIA=multifocal aggressive infiltrates and/or myocyte damage, IIIB= diffuse inflammatory process with necrosis, IV= diffuse aggressive polymorphous and/or infiltrate and/or edema and/or hemorrhage and/or vasculitis, with necrosis</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 6 months, Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 6 months, Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months, Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Daclizumab and Placebo for 6 months were presented</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Daclizumab and Placebo for 12 months were presented</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT</title>
        <description>The median time to first acute rejection episode within first 6 months and 12 months PT was reported.</description>
        <time_frame>Within 6 months and 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified timepoints are denoted by 'n'.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT</title>
          <description>The median time to first acute rejection episode within first 6 months and 12 months PT was reported.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified timepoints are denoted by 'n'.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 6 months (n= 77, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="2" upper_limit="210"/>
                    <measurement group_id="O2" value="21" lower_limit="1" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months (n=97, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="2" upper_limit="372"/>
                    <measurement group_id="O2" value="26" lower_limit="1" upper_limit="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT</title>
        <description>The number of participants who received monomurab Cluster of differentiation 3, orthoclone, polyclonal antithymocyte globulin or antilymphocyte globulin for treatment of biopsy proven rejection or HDC within 6 and 12 months PT were reported.</description>
        <time_frame>Within 6 months and 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT</title>
          <description>The number of participants who received monomurab Cluster of differentiation 3, orthoclone, polyclonal antithymocyte globulin or antilymphocyte globulin for treatment of biopsy proven rejection or HDC within 6 and 12 months PT were reported.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT</title>
        <description>The maintenance doses of mycophenolate mofetil (1.5g twice a day daily), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg oral [PO]/nasogastric [NG] within 72 hours post-operative]), and cumulative dose of corticosteroids (500-1000 mg IV methylprednisolone pre-operative switched to oral at 0.5-1 mg/kg/day. Tapered to 0.2 mg/kg/d by Day 28, 0.1-0.15 mg/kg/day from Days 36 to 90, and 0.1-0.15 mg/kg/day from Days 120 to 180)at 6 and 12 months PT were reported. Maintenance dose was calculated as total dose per day summed over all days that a participant was administered drug within the specified time interval, divided by number of days that a participant took drug within that time interval.</description>
        <time_frame>Within 6 months and 12 months PT</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified timepoints are denoted by 'n'.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT</title>
          <description>The maintenance doses of mycophenolate mofetil (1.5g twice a day daily), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg oral [PO]/nasogastric [NG] within 72 hours post-operative]), and cumulative dose of corticosteroids (500-1000 mg IV methylprednisolone pre-operative switched to oral at 0.5-1 mg/kg/day. Tapered to 0.2 mg/kg/d by Day 28, 0.1-0.15 mg/kg/day from Days 36 to 90, and 0.1-0.15 mg/kg/day from Days 120 to 180)at 6 and 12 months PT were reported. Maintenance dose was calculated as total dose per day summed over all days that a participant was administered drug within the specified time interval, divided by number of days that a participant took drug within that time interval.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified timepoints are denoted by 'n'.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MMF dose, 6 months PT (n=193, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2522.2" spread="791"/>
                    <measurement group_id="O2" value="2450" spread="748.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMF dose,12 months PT (n=188, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2394.1" spread="808"/>
                    <measurement group_id="O2" value="2380.1" spread="779.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Cyclosporine dose, 6 months PT (n=2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.11" spread="102.7"/>
                    <measurement group_id="O2" value="38.1">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Cyclosporine dose, 12 months PT (n=4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" spread="84.3"/>
                    <measurement group_id="O2" value="46.7" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PO/NG Cyclosporine dose, 6 months PT (n=184, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.9" spread="106.6"/>
                    <measurement group_id="O2" value="331.1" spread="121.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PO/NG Cyclosporine dose, 12 months PT (n=170, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.7" spread="93.8"/>
                    <measurement group_id="O2" value="305.7" spread="116.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative corticosteroids,6 months PT(n=203, 206)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848.1" spread="402"/>
                    <measurement group_id="O2" value="955.4" spread="442.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative corticosteroids,12 months PT(n=195,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1199.6" spread="771.8"/>
                    <measurement group_id="O2" value="1288.9" spread="796.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)</title>
        <description>Lipid profile included total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL), and triglycerides (all total cholesterol, LDL, HDL, and triglycerides with unit milligram per decilitre [mg/dL]), were reported. The median change from baseline (Day -2) in lipid profile values at 3 months and 6 months was reported.</description>
        <time_frame>From Baseline (Day -2) to 3 months and 6 months</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified parameters are denoted by 'n'.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)</title>
          <description>Lipid profile included total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL), and triglycerides (all total cholesterol, LDL, HDL, and triglycerides with unit milligram per decilitre [mg/dL]), were reported. The median change from baseline (Day -2) in lipid profile values at 3 months and 6 months was reported.</description>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not. The number of participants analyzed for the specified parameters are denoted by 'n'.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol, change at 3 months (n=119,119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="-3.23" upper_limit="5.69"/>
                    <measurement group_id="O2" value="0.91" lower_limit="-2.20" upper_limit="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol, change at 6 months (n=126,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="-3.75" upper_limit="6.59"/>
                    <measurement group_id="O2" value="0.61" lower_limit="-2.72" upper_limit="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL, Change at 3 months (n=92,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="-3.35" upper_limit="4.84"/>
                    <measurement group_id="O2" value="0.34" lower_limit="-2.47" upper_limit="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL, Change at 6 months (n=91,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-2.86" upper_limit="3.98"/>
                    <measurement group_id="O2" value="0.21" lower_limit="-2.70" upper_limit="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, change at 3 months (n=97, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="-1.27" upper_limit="1.72"/>
                    <measurement group_id="O2" value="0.31" lower_limit="-1.48" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, change at 6 months (n=102,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="-1.53" upper_limit="1.69"/>
                    <measurement group_id="O2" value="0.20" lower_limit="-1.30" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides,change at 3 months (n=104,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="-9.42" upper_limit="3.71"/>
                    <measurement group_id="O2" value="0.46" lower_limit="-12.5" upper_limit="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides,change at 6 months (n=109,117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="-6.48" upper_limit="8.48"/>
                    <measurement group_id="O2" value="0.44" lower_limit="-11.3" upper_limit="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL/HDL ratio,change at 3 months (n=91,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-4.33" upper_limit="9.41"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-6.73" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL/HDL ratio,change at 6 months (n=91, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-4.45" upper_limit="3.83"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-6.01" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline for LDL/HDL Ratio</title>
        <time_frame>From Baseline (Day -2) to 3 months, and 6 months</time_frame>
        <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline for LDL/HDL Ratio</title>
          <population>The randomized population included all participants who were randomized into the study, whether they received the study drug or not.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL/HDL ratio,change at 3 months (n=91,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-4.33" upper_limit="9.41"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-6.73" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL/HDL ratio,change at 6 months (n=91, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-4.45" upper_limit="3.83"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-6.01" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters</title>
        <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Hematology included hemoglobin, hematocrit, white blood cell count (WBC) with differential (including granulocytes or neutrophils, basophils, eosinophils, monocytes, lymphocytes), platelets, and erythrocyte count</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc). The number of participants analyzed for the specified parameters are denoted by n.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters</title>
          <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Hematology included hemoglobin, hematocrit, white blood cell count (WBC) with differential (including granulocytes or neutrophils, basophils, eosinophils, monocytes, lymphocytes), platelets, and erythrocyte count</description>
          <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc). The number of participants analyzed for the specified parameters are denoted by n.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit-high (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit-low (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin-high (n=210, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin-low (n=210, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets-high (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets-low (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC-high (n=209, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC-low (n=209, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils-high (n=199, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils-high (n=199, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes-high (n=199, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes-low (n=199, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes-high (n=199, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes-low (n=199, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils-low (n= 199, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC-high (n=207, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC-low (n=207, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters</title>
        <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Biochemistry included blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), phosphorous, total bilirubin, direct bilirubin, total protein, albumin, glucose, alkaline phosphatase, low density lipoprotein (LDH), uric acid, carbon dioxide, magnesium, sodium, potassium, chloride, calcium, LDL, HDL, total cholesterol, and triglycerides.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc). The number of participants analyzed for the specified parameters are denoted by n.</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters</title>
          <description>A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Biochemistry included blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), phosphorous, total bilirubin, direct bilirubin, total protein, albumin, glucose, alkaline phosphatase, low density lipoprotein (LDH), uric acid, carbon dioxide, magnesium, sodium, potassium, chloride, calcium, LDL, HDL, total cholesterol, and triglycerides.</description>
          <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc). The number of participants analyzed for the specified parameters are denoted by n.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGPT-high (n=200, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP-high (n=201, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGOT-high (n=201, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT-high (n=180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH-high (n=194, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin-high (n=201, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN-high (n= 210, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine-high (n=211, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin-low (n=198,197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein-high (n=195,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein-low(n=195,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol-high (n=174, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides-high (n=164, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbondioxide-high (n=206, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbondioxide-low (n=206, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride-high (n=211, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride-low (n=211, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium-high (n=211, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium-low (n=211, 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium-high (n=211, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium-low (n=211, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium-low (n=207, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose fasting-high (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose fasting-low (n=210, 203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-high (n=199, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-low (n=199,194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid high (n=191, 188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during this study were reported as AEs. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc).</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during this study were reported as AEs. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.</description>
          <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                    <measurement group_id="O2" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AEs leading to premature discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Malignancies and Opportunistic Infections</title>
        <description>The opportunistic infections included infections with Cytomegalovirus, Aspergillus, Candida, Pneumocystis, Cryptococcus, Listeria, Herpes simplex, Herpes zoster. For malignancy, participants with any type of malignancy whose date of onset or diagnosis was after randomization was reported.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc).</population>
        <group_list>
          <group group_id="O1">
            <title>Daclizumab</title>
            <description>Eligible participants were administered an intravenous (IV) dose of daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Eligible participants were administered an IV dose of matching placebo (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID]), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Malignancies and Opportunistic Infections</title>
          <description>The opportunistic infections included infections with Cytomegalovirus, Aspergillus, Candida, Pneumocystis, Cryptococcus, Listeria, Herpes simplex, Herpes zoster. For malignancy, participants with any type of malignancy whose date of onset or diagnosis was after randomization was reported.</description>
          <population>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with opportunistic infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months</time_frame>
      <desc>Safety population included all participants who received at least one dose of study drug (daclizumab or placebo) or commercially available daclizumab and have at least one post-baseline safety assessment (eg. any laboratory data, adverse event, etc). The number of participants analyzed for the specified parameters are denoted by n.</desc>
      <group_list>
        <group group_id="E1">
          <title>Daclizumab</title>
          <description>Eligible participants were administered an intravenous daclizumab (1 milligrams per kilogram [mg/kg]) on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Eligible participants were administered an IV dose of matching placebo on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine (1-4 mg/kg IV or 2-6 mg/kg orally/nasogastric), and corticosteroid (methylprednisolone, 500-1000 mg IV pre-operative switch to oral at 0.5-1 mg/kg/day followed by tapering). Participants received mycophenolate mofetil, cyclosporine, and corticosteroid up to 365 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Leukopenia nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrioventricular block nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bradycardia nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiac failure nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Coronary artery disease nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Endocarditis nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post myocardial infarction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tachycardia nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Antibiotic associated colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Caecum perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Food poisoning nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastritis nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Mesenteric occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Toxic dilatation of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Debility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Humoral immune defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Clostridial infection nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Empyema nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pleural infection nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia gram-negative bacterial nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia nos</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Purulent pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Sepsis nos</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Septicaemia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Septicaemia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Viral infection nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Wound infection nec</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Aortic injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Postoperative haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Therapeutic agent poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Traumatic chest injury nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Upper limb fracture nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function tests nos abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperglycemia nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Myopathy steroid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenoma benign nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Precancerous skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Convulsions nos</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Encephalopathy nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Headache nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Intracranial haemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Migraine nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Depression nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus renal nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Loin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal failure nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal impairment nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Mediastinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumothorax nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Respiratory failure (excl neonatal)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Excessive bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Deep venous thrombosis nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Haemorrhage nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypertension nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypotension nos</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Venous thrombosis deep limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia nos</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Leukopenia nos</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia nos</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Bradycardia nos</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pericardial rub</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tachycardia nos</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Abdominal pain nos</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Diarrhoea nos</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gastrointestinal upset</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Vomiting nos</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oedema lower limb</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oedema nos</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pain nos</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis nos</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumonia nos</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection nos</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Urinary tract infection nos</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function tests nos abnormal</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus nos</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia nos</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia nos</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia nos</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis nos</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness (excl vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Headache nos</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Anxiety nec</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Depression nos</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Renal impairment nos</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Breath sounds decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Dyspnoea nos</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pneumothorax nos</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne nos</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pressure sore</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Rash nos</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension nos</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Hypotension nos</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension nos</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

